Aurinia Pharmaceuticals Inc. (AUPH) Income Statement
AUPH 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsAUPH revenue and net income
Where AUPH's revenue goes
2025Each bar shows an amount and its share of revenue. AUPH kept 101.5% of revenue as net income.
AUPH profit margins
AUPH growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +20.4% | +28.3% | +41.4% | +103.3% |
| Gross profit | +21.0% | +24.9% | +38.0% | +101.9% |
| Operating income | — | — | — | — |
| Net income | +4,893.1% | — | — | — |
| EPS (diluted) | +1,520.0% | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
AUPH quarterly EPS vs estimates
Aurinia Pharmaceuticals beat the analyst EPS estimate in 8 of the last 8 quarters. Next report: November 3, 2026 (estimate $0.21).
AUPH income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $283.1M | $235.1M | $175.5M | $134.0M | $45.6M | $50.1M | $318,000 | $463,000 | $420,000 | $173,000 |
| Cost of revenue | $32.7M | $28.2M | $14.1M | $5.7M | $1.1M | $50.3M | $52.9M | $41.4M | $1,000 | $4,000 |
| Gross profit | $250.4M | $206.9M | $161.4M | $128.4M | $44.5M | $50.1M | $318,000 | −$40.9M | $419,000 | $169,000 |
| Research & development | $32.5M | $20.8M | $49.6M | $45.0M | $51.1M | $50.3M | $52.9M | $41.4M | $33.9M | $14.5M |
| Sales, general & admin | $101.8M | $172.0M | $195.0M | $196.4M | $171.4M | $97.3M | $22.3M | $13.7M | $12.1M | $7.0M |
| Total operating expenses | $145.5M | $211.6M | $253.1M | $239.8M | $225.2M | $154.4M | $91.3M | $56.6M | $47.5M | $23.0M |
| Operating income | $104.9M | −$4.7M | −$91.7M | −$111.5M | −$180.7M | −$104.3M | −$90.9M | −$56.2M | −$47.1M | −$22.8M |
| Interest income | $13.6M | $17.0M | $15.3M | $5.1M | $529,000 | $1.5M | $2.7M | $2.2M | $1.0M | $27,000 |
| Interest expense | $4.3M | $4.8M | $2.8M | $5.1M | $529,000 | $5.3M | $39,000 | $2.2M | $702,000 | $27,000 |
| Income before taxes | $114.2M | $7.4M | −$77.5M | −$106.4M | −$180.2M | −$102.8M | −$88.2M | −$64.0M | −$70.8M | −$23.3M |
| Income taxes | −$173.0M | $1.7M | $551,000 | $1.8M | $760,000 | −$94,000 | $144,000 | $73,000 | $23.9M | $481,000 |
| Net income | $287.2M | $5.8M | −$78.0M | −$108.2M | −$181.0M | −$102.7M | −$88.4M | −$64.1M | −$70.8M | −$23.3M |
| EBITDA | $127.8M | $31.7M | −$63.0M | −$108.8M | −$177.4M | −$102.9M | −$89.8M | −$53.9M | −$45.6M | −$21.3M |
| EPS (diluted) | $0.81 | $0.05 | −$0.54 | −$0.76 | −$1.41 | −$0.84 | −$1.32 | −$0.69 | −$0.52 | −$0.65 |
| Gross margin | 88.5% | 88.0% | 91.9% | 95.8% | 97.6% | 100.0% | 100.0% | −8,837.8% | 99.8% | 97.7% |
| Operating margin | 37.1% | −2.0% | −52.2% | −83.2% | −396.3% | −208.1% | −28,598.4% | −12,129.2% | −11,205.5% | −13,187.3% |
| Net margin | 101.5% | 2.4% | −44.5% | −80.7% | −396.8% | −204.9% | −27,794.0% | −13,848.8% | −16,855.2% | −13,465.3% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $83.2M | $77.7M | $77.1M | $73.5M | $70.0M | $62.5M | $59.9M | $67.8M | $57.2M | $50.3M | $45.1M | $54.5M |
| Cost of revenue | $6.6M | $6.5M | $8.5M | $8.5M | $7.1M | $8.6M | $5.6M | $6.0M | $8.9M | $7.8M | $5.4M | $6.8M |
| Gross profit | $76.7M | $71.2M | $68.6M | $65.0M | $62.9M | $53.9M | $54.3M | $61.7M | $48.3M | $42.6M | $39.7M | $47.7M |
| Research & development | $13.1M | $7.5M | $10.9M | $8.4M | $7.4M | $5.7M | $8.1M | $3.0M | $4.1M | $5.6M | $10.2M | $13.6M |
| Sales, general & admin | $23.5M | $22.0M | $28.5M | $26.2M | $26.0M | $20.3M | $45.3M | $42.4M | $44.9M | $47.7M | $50.1M | $47.8M |
| Total operating expenses | $30.3M | $29.8M | $35.4M | $35.2M | $42.8M | $32.0M | $56.0M | $50.0M | $49.8M | $53.2M | $60.3M | $64.0M |
| Operating income | $46.3M | $41.4M | $33.2M | $29.7M | $20.1M | $21.8M | −$1.7M | $11.7M | −$1.5M | −$10.7M | −$20.6M | −$16.3M |
| Interest income | $3.4M | $3.5M | $3.5M | $3.3M | $3.2M | $3.6M | $4.0M | $4.3M | $4.2M | $4.5M | $4.6M | $4.5M |
| Interest expense | $948,000 | $1.0M | $6.5M | $1.1M | $1.1M | $1.1M | $1.1M | $1.2M | $1.2M | $1.3M | $1.3M | $1.4M |
| Income before taxes | $48.8M | $43.9M | $35.7M | $32.0M | $22.2M | $24.3M | $1.2M | $14.8M | $1.5M | −$10.0M | −$26.4M | −$13.1M |
| Income taxes | $11.4M | $9.6M | −$175.1M | $411,000 | $643,000 | $1.0M | −$256,000 | $457,000 | $756,000 | $739,000 | $459,000 | $298,000 |
| Net income | $37.4M | $34.4M | $210.8M | $31.6M | $21.5M | $23.3M | $1.4M | $14.3M | $722,000 | −$10.7M | −$26.9M | −$13.4M |
| EBITDA | $54.6M | $49.8M | $47.1M | $36.8M | $28.1M | $30.3M | $7.2M | $20.9M | $7.5M | −$3.9M | −$15.7M | −$6.5M |
| EPS (diluted) | $0.28 | $0.25 | $0.26 | $0.23 | $0.16 | $0.16 | $0.01 | $0.10 | $0.01 | −$0.07 | −$0.19 | −$0.09 |
| Gross margin | 92.1% | 91.6% | 89.0% | 88.4% | 89.8% | 86.3% | 90.7% | 91.1% | 84.4% | 84.6% | 88.0% | 87.6% |
| Operating margin | 55.7% | 53.3% | 43.1% | 40.5% | 28.7% | 35.0% | −2.8% | 17.3% | −2.6% | −21.3% | −45.7% | −29.8% |
| Net margin | 45.0% | 44.2% | 273.4% | 42.9% | 30.7% | 37.4% | 2.4% | 21.2% | 1.3% | −21.4% | −59.6% | −24.7% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in AUPH's financial statements (latest annual report filed February 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
AUPH financial results
In fiscal year 2025 (ended December 31, 2025), Aurinia Pharmaceuticals reported revenue of $283.1 million, up 20.4% from the year before. It had net income of $287.2 million (up 4,893.1%), a net profit margin of 101.5%. Diluted earnings per share came to $0.81. Over five years revenue grew at an average rate of 41.4% a year.
See the AUPH stock overview for the latest quote and news, or the AUPH chart for price history and technical indicators.
AUPH income statement FAQ
What is Aurinia Pharmaceuticals's annual revenue?
Aurinia Pharmaceuticals reported total revenue of $283.1 million for fiscal year 2025, which ended on December 31, 2025. That was up 20.4% from $235.1 million the previous year.
Is Aurinia Pharmaceuticals profitable?
Yes. Aurinia Pharmaceuticals reported net income of $287.2 million in fiscal 2025, a net profit margin of 101.5%; its operating margin was 37.1%.
What is Aurinia Pharmaceuticals's gross margin?
Aurinia Pharmaceuticals's gross margin was 88.5% in fiscal 2025: for every $100 of revenue, Aurinia Pharmaceuticals kept $88 after the direct cost of its products and services.
How much does Aurinia Pharmaceuticals spend on research and development?
Aurinia Pharmaceuticals spent $32.5 million on research and development in fiscal 2025, 11.5% of revenue.
How fast is Aurinia Pharmaceuticals growing?
Revenue grew 41.4% a year on average over the last five fiscal years, from $50.1 million to $283.1 million.
What are Aurinia Pharmaceuticals's earnings per share?
Aurinia Pharmaceuticals earned $0.81 per diluted share in fiscal 2025, compared with $0.05 a year earlier.
When will Aurinia Pharmaceuticals report its next earnings?
Aurinia Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 3, 2026.
When does Aurinia Pharmaceuticals's fiscal year end?
Aurinia Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 26, 2026.